Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13739933 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3671431 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17700060 | 0.93 | SIGMAR1 (0.57) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL785198 | 0.92 | SIGMAR1 (0.58) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25257016 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25257018 | 0.92 | SIGMAR1 (0.61) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13012605 | 0.91 | SMN1; SMN2 (0.57) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30829344 | 0.90 | SIGMAR1 (0.54) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7761338 | 0.86 | USP30 (0.62) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL28030595 | 0.86 | USP30 (0.62) | SIGMAR1CCR5SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10064839-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9561209-B2 | Methods of treating liver diseases | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-2705030-B1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9290472-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2916833-A1 | METHODS OF TREATING LIVER DISEASES | Zafgen, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014071368-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012154676-A9 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2705030-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001973-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | SIGMAR1 1234/4885CCR5 2793/4885SMN1; SMN2 3316/4885 |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | SIGMAR1 2348/4885CCR5 2468/4885SMN1; SMN2 4364/4885 |
| US-10064839-B2 | Methods of treating liver diseases | ENPEP, GOT2, METAP2 | SIGMAR1 2348/4885CCR5 2468/4885SMN1; SMN2 4364/4885 |
| US-20160058731-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | SIGMAR1 2348/4885CCR5 2468/4885SMN1; SMN2 4364/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | SIGMAR1 1234/4885CCR5 2793/4885SMN1; SMN2 3316/4885 |
| US-20140088078-A1 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same | DNPEP, CES2, AADAC | SIGMAR1 1234/4885CCR5 2793/4885SMN1; SMN2 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.